– Dr. Rakesh Jetly, OMM, CD, MD, FRCPC
Dr. Jetly serves as Chief Medical Officer for Mydecine Innovations Group. Dr. Jetly brings to Mydecine a wealth of experience not only as a medical advocate for the use of psychedelic-assisted psychotherapy, but also as a prominent voice in the fight against post-traumatic stress disorder (PTSD) and other mental health issues facing vulnerable populations like veterans and first responders. Dr. Jetly currently serves as Academic Chair of Military Mental Health at The Royal’s Institute of Mental Health Research, and as an associate professor of psychiatry at Dalhousie University (Halifax), and the University of Ottawa. In 2015, he was appointed, “The Canadian Forces Brigadier Jonathan C. Meakins, CBE, RCAMC Chair in Military Mental Health.” He has published numerous articles in professional journals and presents nationally and internationally on such topics as PTSD and operational psychiatry.
As Chief Medical Officer, Dr. Jetly will lead Mydecine’s clinical trials related to psychedelic-assisted psychotherapy using psilocybin to treat PTSD. Dr. Jetly will also keep Mydecine abreast of new scientific research related to psychedelics, and offer strategic guidance as it relates to all aspects of patient care, medical safety, medical compliance and the administration of psychedelics. Additionally, Dr. Jetly will also engage medical professionals and veterans’ organizations through outreach and educational offerings regarding the use of psychedelics as medicine
– Robert Roscow, MA, Mydecine CSO
Mr. Roscow is a highly educated geneticist with impressive knowledge around multiple arts of science. He has spent his academic and professional careers looking for valuable and unique active medicinal compounds found in nature. The last two companies Mr. Roscow applied his innovations to were Canopy Growth and ebbu where he was the head of their genetics divisions.
Mr. Roscow has already leveraged an expertise in genomics, evolution, and molecular biology to maximize the industrial production of cannabinoids and their use in a pharmacological context. His work has resulted in multiple patent filings and accolades in publications ranging from Nature to Rolling Stone. Now, Mr. Roscow has set his focus on the vast healing potential of the safe and effective compounds found in fungi.
– Robin Carhart-Harris, Ph.D
Dr Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA in Psychoanalysis from Brunel University. At Imperial, Robin has designed and completed human brain imaging studies with LSD, psilocybin, MDMA and DMT, a clinical trial of psilocybin for treatment-resistant depression, a double-blind randomised controlled trial comparing psilocybin with escitalopram for major depressive disorder and a multimodal imaging study in healthy volunteers receiving psilocybin for the first time. Robin founded the Centre for Psychedelic Research at Imperial College London in April 2019, the first of its kind in the world.
– Ruth Lanius, MD, Ph.D.
Ruth is Professor of Psychiatry and the director of the posttraumatic stress disorder (PTSD) research unit at the University of Western Ontario.
She established the Traumatic Stress Service and the Traumatic Stress Service Workplace Program, both services that specialize in the treatment and research of Posttraumatic Stress Disorder (PTSD) and related comorbid disorders.
Ruth currently holds the Harris-Woodman Chair in Mind-Body Medicine at the Schulich School of Medicine & Dentistry at the University of Western Ontario. Her research interest focus on studying the neurobiology of PTSD and treatment outcome research examining various pharmacological and psychotherapeutic methods.
Ruth has authored more than 100 published papers and chapters in the field of traumatic stress and is currently funded by several federal funding agencies. She regularly lectures on the topic of PTSD nationally and internationally. She has recently published a book Healing the traumatized self: consciousness, neuroscience, treatment with Paul Frewen which we talk about in the interview.